In which neonates should exogenous surfactant be administered, including gestational age, respiratory distress syndrome criteria, and conditions such as severe meconium aspiration, pulmonary hemorrhage, or persistent pulmonary hypertension?

Surfactant Indications in Neonates

Preterm infants born at <30 weeks' gestation who require mechanical ventilation for severe RDS should receive surfactant after initial stabilization, while CPAP with selective surfactant administration should be considered as the preferred alternative to routine intubation in extremely preterm infants. 1

Primary Indications by Gestational Age and Clinical Presentation

Preterm Infants <30 Weeks' Gestation

For infants <26 weeks' gestation:

• Administer prophylactic surfactant if intubation is required in the delivery room 2
• If antenatal steroids were complete and infant is stable without intubation need, initiate CPAP immediately after birth with subsequent selective surfactant administration 1

For infants 26-30 weeks' gestation:

• Preferred approach: Start CPAP immediately after birth, then give early rescue surfactant (<2 hours of age) if the infant requires intubation during follow-up 1
• This CPAP-first strategy with selective surfactant results in lower rates of BPD/death compared to prophylactic surfactant therapy 1
• Early rescue surfactant (<2 hours) decreases mortality, air leak, and chronic lung disease risk 1

Critical Timing Considerations

The evidence strongly supports early administration:

• Early rescue treatment (<2 hours of age) reduces mortality, pneumothorax, pulmonary interstitial emphysema, and chronic lung disease 1
• Delayed surfactant administration is associated with poorer outcomes 3
• Responders to surfactant received treatment earlier (median 7.2 hours) versus nonresponders (median 15.6 hours) 3

Secondary Surfactant Deficiency Conditions

Rescue surfactant may be considered for infants with hypoxic respiratory failure attributable to secondary surfactant deficiency 1:

Meconium Aspiration Syndrome

• Surfactant treatment improves oxygenation and reduces the need for ECMO without increasing morbidity 1
• Level of evidence: 2 1
• However, response may be suboptimal if PPHN is present 3

Pulmonary Hemorrhage

• May be considered as rescue therapy 1
• Evidence is limited but suggests potential benefit 4

Pneumonia/Sepsis

• May be considered for hypoxic respiratory failure 1
• Limited evidence supports use, but can be a feasible option 4

Persistent Pulmonary Hypertension (PPHN)

• Important caveat: PPHN is significantly associated with less improvement in oxygenation post-surfactant (p < 0.001) 3
• Suboptimal response to surfactant should prompt investigation for underlying PPHN 3
• Concomitant management of PPHN is critically important 5

Conditions Where Surfactant is NOT Indicated

Congenital diaphragmatic hernia:

• Surfactant treatment does not improve clinical outcomes 1
• Level of evidence: 2 1
• Do not administer surfactant for this condition

Important Clinical Caveats

Air Leaks

• Air leaks (pneumothorax, pulmonary interstitial emphysema) are significantly associated with less improvement post-surfactant (p = 0.001) 3
• Despite this, surfactant reduces the overall incidence of air leaks when given early 1

Antenatal Steroids

• Antenatal steroids and postnatal surfactant independently and additively reduce mortality, RDS severity, and air leaks 1
• Antenatal steroids may reduce the need for surfactant in infants born after 27-28 weeks' gestation 1
• However, in infants ≤27 weeks' gestation, RDS incidence is not reduced by antenatal steroids alone 1

Late Preterm Infants (≥34 Weeks)

• Surfactant improves oxygenation in late preterm infants, though response depends on timing and comorbidities 3
• 64% demonstrate good response; 81% of responders maintain sustained improvement 3
• Do not withhold surfactant solely based on gestational age 3

Administration Requirements

Critical safety consideration: Preterm and term neonates receiving surfactant should be managed by nursery and transport personnel with technical and clinical expertise to administer surfactant safely and manage multisystem illness. Providers without expertise should wait for the transport team to arrive 1.

Surfactant Type

• Natural (animal-derived) surfactants and newer synthetic surfactants with SP-B-like activity both decrease acute respiratory morbidity and mortality 1
• Natural surfactants have demonstrated clinical superiority over older synthetic preparations 6, 7